Table 3.
FH mutation detection rate by quartile of pre-treatment TC and pre-treatment TG.
| Oxford FH study | |||||
|---|---|---|---|---|---|
| Quartile of pre-treatment TC (mmol/l) | N | Mutation + ve (%) | Quartile of pre-treatment TG (mmol/l) | N | Mutation + ve (%) |
| Q1 ≤8.0 | 40 | 10 (25) | Q1 ≤1.0 | 42 | 25 (60) |
| Q2 8.1–8.7 | 41 | 12 (29) | Q2 1.10–1.32 | 38 | 15 (40) |
| Q3 8.8–9.9 | 44 | 15 (34) | Q3 1.33–2.15 | 39 | 14 (36) |
| Q4 >10.0 | 34 | 25 (74) | Q4 2.16–4.30 | 40 | 8 (20) |
| P value (trend) | p = 9.83 × 10−5 | 0.000458 | |||
| Replication SBBHF study | |||||
|---|---|---|---|---|---|
| Quartile of pre-treatment TC (mmol/l) | N | Mutation + ve (%) | Quartile of post-treatment TG (mmol/l)a | N | Mutation + ve (%) |
| Q1 ≤8.7 | 76 | 52 (68.4) | Q1 <1 | 105 | 92 (87.6) |
| Q2 8.8–10.1 | 82 | 66 (80.5) | Q2 1–1.3 | 123 | 109 (88.6) |
| Q3 10.2–11.6 | 69 | 62 (89.9) | Q3 1.4–1.8 | 90 | 70 (77.8) |
| Q4 >11.6 | 72 | 65 (90.3) | Q4 >1.8 | 91 | 57 (62.6) |
| P value (trend) | 0.0001 | P = 1.80 × 10−6 | |||
a
Pre-treatment TG were not available for SBBHF study.